Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Chinook Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Chinook Therapeutics"},{"company":"Altasciences Company Inc","sponsor":"Alladapt Immunotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Altasciences Continues Manufacturing Expansion in Philadelphia With Client\u2011Dedicated Building Project","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"CANADA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Altasciences Company Inc"}]

Altasciences Company Inc

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Altasciences Continues Manufacturing Expansion in Philadelphia With Client‑Dedicated Building Project

Details:

Alladapt in their important goal of developing a single therapeutic ADP101, to address a wide range of mono- and multi-food allergies, and looking forward to fulfilling their Phase III and commercial requirements.

Lead Product(s): ADP101

Therapeutic Area: Immunology Product Name: ADP101

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Alladapt Immunotherapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement July 15, 2022

ASK
US

Upload
your Pipeline Activity

Chinook Therapeutics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Aduro Biotech Announces First Patient Dosed in Phase 1 Study of BION-1301 in IgA Nephropathy

Details:

Part 3 of the Phase 1 multi-center trial is evaluating the safety and tolerability of BION-1301 in two cohorts of 20 total adult subjects with IgA nephropathy in an open-label multiple dose design.

Lead Product(s): BION-1301

Therapeutic Area: Immunology Product Name: BION-1301

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY